HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In VitroLenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy

MLA

Nelde, Annika, et al. “HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In VitroLenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy.” Blood, vol. 128, no. 22, Jan. 2016, p. 3234. EBSCOhost, https://doi.org/10.1182/blood.V128.22.3234.3234.

APA

Nelde, A., Kowalewski, D. J., Backert, L., Schuster, H., Kanz, L., Salih, H. R., Rammensee, H.-G., Stevanovic, S., & Stickel, J. S. (2016). HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In VitroLenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy. Blood, 128(22), 3234. https://doi.org/10.1182/blood.V128.22.3234.3234

Chicago

Nelde, Annika, Daniel J. Kowalewski, Linus Backert, Heiko Schuster, Lothar Kanz, Helmut R. Salih, Hans-Georg Rammensee, Stefan Stevanovic, and Juliane S. Stickel. 2016. “HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In VitroLenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy.” Blood 128 (22): 3234. doi:10.1182/blood.V128.22.3234.3234.